Behavioral consequences of NMDA antagonist-induced neuroapoptosis in the infant mouse brain.

Exposure to NMDA glutamate antagonists during the brain growth spurt period causes widespread neuroapoptosis in the rodent brain. This period in rodents occurs during the first two weeks after birth, and corresponds to the third trimester of pregnancy and several years after birth in humans. The dev...

Full description

Bibliographic Details
Main Authors: Carla M Yuede, David F Wozniak, Catherine E Creeley, George T Taylor, John W Olney, Nuri B Farber
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2010-06-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC2894063?pdf=render
_version_ 1819102633853452288
author Carla M Yuede
David F Wozniak
Catherine E Creeley
George T Taylor
John W Olney
Nuri B Farber
author_facet Carla M Yuede
David F Wozniak
Catherine E Creeley
George T Taylor
John W Olney
Nuri B Farber
author_sort Carla M Yuede
collection DOAJ
description Exposure to NMDA glutamate antagonists during the brain growth spurt period causes widespread neuroapoptosis in the rodent brain. This period in rodents occurs during the first two weeks after birth, and corresponds to the third trimester of pregnancy and several years after birth in humans. The developing human brain may be exposed to NMDA antagonists through drug-abusing mothers or through anesthesia.We evaluated the long-term neurobehavioral effects of mice exposed to a single dose of the NMDA antagonist, phencyclidine (PCP), or saline, on postnatal day 2 (P2) or P7, or on both P2 and P7. PCP treatment on P2 + P7 caused more severe cognitive impairments than either single treatment. Histological examination of acute neuroapoptosis resulting from exposure to PCP indicated that the regional pattern of degeneration induced by PCP in P2 pups was different from that in P7 pups. The extent of damage when evaluated quantitatively on P7 was greater for pups previously treated on P2 compared to pups treated only on P7.These findings signify that PCP induces different patterns of neuroapoptosis depending on the developmental age at the time of exposure, and that exposure at two separate developmental ages causes more severe neuropathological and neurobehavioral consequences than a single treatment.
first_indexed 2024-12-22T01:37:40Z
format Article
id doaj.art-1aa4e09181e140a0bb0aa3a5d7b1eed2
institution Directory Open Access Journal
issn 1932-6203
language English
last_indexed 2024-12-22T01:37:40Z
publishDate 2010-06-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj.art-1aa4e09181e140a0bb0aa3a5d7b1eed22022-12-21T18:43:18ZengPublic Library of Science (PLoS)PLoS ONE1932-62032010-06-0156e1137410.1371/journal.pone.0011374Behavioral consequences of NMDA antagonist-induced neuroapoptosis in the infant mouse brain.Carla M YuedeDavid F WozniakCatherine E CreeleyGeorge T TaylorJohn W OlneyNuri B FarberExposure to NMDA glutamate antagonists during the brain growth spurt period causes widespread neuroapoptosis in the rodent brain. This period in rodents occurs during the first two weeks after birth, and corresponds to the third trimester of pregnancy and several years after birth in humans. The developing human brain may be exposed to NMDA antagonists through drug-abusing mothers or through anesthesia.We evaluated the long-term neurobehavioral effects of mice exposed to a single dose of the NMDA antagonist, phencyclidine (PCP), or saline, on postnatal day 2 (P2) or P7, or on both P2 and P7. PCP treatment on P2 + P7 caused more severe cognitive impairments than either single treatment. Histological examination of acute neuroapoptosis resulting from exposure to PCP indicated that the regional pattern of degeneration induced by PCP in P2 pups was different from that in P7 pups. The extent of damage when evaluated quantitatively on P7 was greater for pups previously treated on P2 compared to pups treated only on P7.These findings signify that PCP induces different patterns of neuroapoptosis depending on the developmental age at the time of exposure, and that exposure at two separate developmental ages causes more severe neuropathological and neurobehavioral consequences than a single treatment.http://europepmc.org/articles/PMC2894063?pdf=render
spellingShingle Carla M Yuede
David F Wozniak
Catherine E Creeley
George T Taylor
John W Olney
Nuri B Farber
Behavioral consequences of NMDA antagonist-induced neuroapoptosis in the infant mouse brain.
PLoS ONE
title Behavioral consequences of NMDA antagonist-induced neuroapoptosis in the infant mouse brain.
title_full Behavioral consequences of NMDA antagonist-induced neuroapoptosis in the infant mouse brain.
title_fullStr Behavioral consequences of NMDA antagonist-induced neuroapoptosis in the infant mouse brain.
title_full_unstemmed Behavioral consequences of NMDA antagonist-induced neuroapoptosis in the infant mouse brain.
title_short Behavioral consequences of NMDA antagonist-induced neuroapoptosis in the infant mouse brain.
title_sort behavioral consequences of nmda antagonist induced neuroapoptosis in the infant mouse brain
url http://europepmc.org/articles/PMC2894063?pdf=render
work_keys_str_mv AT carlamyuede behavioralconsequencesofnmdaantagonistinducedneuroapoptosisintheinfantmousebrain
AT davidfwozniak behavioralconsequencesofnmdaantagonistinducedneuroapoptosisintheinfantmousebrain
AT catherineecreeley behavioralconsequencesofnmdaantagonistinducedneuroapoptosisintheinfantmousebrain
AT georgettaylor behavioralconsequencesofnmdaantagonistinducedneuroapoptosisintheinfantmousebrain
AT johnwolney behavioralconsequencesofnmdaantagonistinducedneuroapoptosisintheinfantmousebrain
AT nuribfarber behavioralconsequencesofnmdaantagonistinducedneuroapoptosisintheinfantmousebrain